Skip to main content
. 2018 Jun 28;13(6):e0199760. doi: 10.1371/journal.pone.0199760

Table 1. Comparsion of patients according to AST level.

Variable All, N = 1716 AST<37, N = 132 37<AST≤74, N = 501 74<AST≤148 IU/L, N = 737 AST>148 IU/L, N = 346 P
Age (years) 52.5±11.6 46.7±12 50.1±12.2 53.9±10.7 55.3±10.7 <0.001
Male gender, N (%) 913 (53.2%) 65 (49.2%) 294 (58.7%) 383 (52.0%) 171 (49.4%) 0.025
Genotype, N (%) 0.099
 1 728 (46.7%) 47 (40.2%) 230 (49.8%) 322 (48.6%) 129 (40.6%)
 2 756 (48.5%) 59 (50.4%) 211 (45.7%) 312 (47.1%) 174 (54.7%)
 Mixed 50 (3.2%) 8 (6.8%) 13 (2.8%) 19 (2.9%) 10 (3.1%)
 Others 26 (1.6%) 3 (2.6%) 8 (1.7%) 10 (1.5%) 5 (1.6%)
 Missing data 156 (9.1%) 15 (11.4%) 39 (7.8%) 74 (10.0%) 28 (8.1%)
BMI (kg/m2) 24.6±3.5 23.8±3.4 24.7±3.4 24.7±3.6 24.7±3.5 0.09
 Missing data 181 (10.6%) 22 (16.7%) 47 (9.4%) 70 (9.5%) 42 (12.1%)
Necroinflammation score 7.3±2.3 5.1±2.0 6.6±2.2 7.7±2.1 8.2±2.3 <0.001
Fibrosis <0.001
 0 325 (18.9%) 77 (58.3%) 128 (25.5%) 73 (9.9%) 47 (13.6%)
 1 483 (28.2%) 23 (17.4%) 178 (35.5%) 209 (28.4%) 73 (21.1%)
 2 163 (9.5%) 9 (6.8%) 48 (9.6%) 78 (10.6%) 28 (8.1%)
 3 309 (18.0%) 17 (12.9%) 65 (13%) 150 (20.4%) 77 (22.3%)
 4 436 (25.4%) 6 (4.5%) 82 (16.4%) 227 (30.8%) 121 (35.0%)
HCV RNA >600,000 IU/ml, N (%) 262 (27.3%) 37 (38.9%) 92 (31.2%) 81 (21.2%) 52 (27.8%) 0.001
Only qualitative HCV RNA was available, N (%) 756 (44.1%) 37 (28%) 206 (41.1%) 354 (48.0%) 159 (46.0%)
ALT (IU/L) 134 (93–205.5) 44 (32–57) 92 (75–111) 152 (120–195) 273.5 (209–366) <0.001
Platelet (109/L) <150 680 (39.6%) 24 (18.2%) 152 (30.3%) 341 (46.3%) 163 (47.1%) <0.001
Bilirubin (mg/dL) 0.9±0.6 0.9±0.5 0.9±0.5 0.9±0.6 1.0±0.8 0.75
Albumin (mg/dL) 3.9±0.6 4.0±0.4 4.2±0.4 3.9±0.6 3.7±0.6 <0.001
INR 1.0±0.1 1.1±0.1 1.0±0.1 1.0±0.1 1.1±0.1 0.04

Data were expressed as mean ± SD or median (interquantile). BMI, body mass index; AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase; INR, international normalized ratio